RXSIGHT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.7 USD | +8.77% |
|
+7.31% | +40.62% |
| Sales 2024 * | 132M 10.51B | Sales 2025 * | 174M 13.92B | Capitalization | 2.11B 168B |
|---|---|---|---|---|---|
| Net income 2024 * | -36M -2.88B | Net income 2025 * | -26M -2.08B | EV / Sales 2024 * | 15.3 x |
| Net cash position 2024 * | 92.68M 7.4B | Net cash position 2025 * | 87M 6.95B | EV / Sales 2025 * | 11.6 x |
| P/E ratio 2024 * |
-57.7
x | P/E ratio 2025 * |
-80.2
x | Employees | 374 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on RxSight, Inc.
More recommendations
More press releases
| 1 day | +8.77% | ||
| 1 week | +7.31% | ||
| Current month | +8.77% | ||
| 1 month | +12.34% | ||
| 3 months | +13.86% | ||
| 6 months | +154.26% | ||
| Current year | +40.62% |
1 week
52.00
57.80
1 month
49.6957.80
Current year
34.9258.21
1 year
18.0958.21
3 years
8.8058.21
5 years
8.8058.21
10 years
8.8058.21
| Managers | Title | Age | Since |
|---|---|---|---|
Ronald Kurtz
CEO | Chief Executive Officer | 60 | 31/05/15 |
Shelley Thunen
DFI | Director of Finance/CFO | 72 | 31/12/15 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Palmisano
BRD | Director/Board Member | 79 | 09/08/21 |
Bill Link
BRD | Director/Board Member | 78 | 31/10/16 |
Ronald Kurtz
CEO | Chief Executive Officer | 60 | 31/05/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +5.00% | - | |
| 0.00% | 147 M€ | +4.63% | - | |
| 0.00% | 34 M€ | +1.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 56.7 | +8.77% | 675,664 |
| 30/04/24 | 52.13 | -2.12% | 305,657 |
| 29/04/24 | 53.26 | +0.93% | 423,365 |
| 26/04/24 | 52.77 | +1.70% | 273,467 |
| 25/04/24 | 51.89 | -1.80% | 364,837 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotes
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.
Calendar
06/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
56.7
USD
Average target price
62.62
USD
Spread / Average Target
+10.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.62% | 2.11B | |
| -3.43% | 184B | |
| -1.81% | 107B | |
| -4.15% | 67.52B | |
| +1.43% | 50.06B | |
| +11.60% | 45.67B | |
| +3.40% | 41B | |
| +3.03% | 26.73B | |
| +3.21% | 26.47B | |
| +15.23% | 25.05B |
- Stock Market
- Equities
- RXST Stock
